How Long Does IGF-1 Stay in Your System? What the Literature Reports

Three different clocks hide inside one question

Asking how long insulin-like growth factor 1 (IGF-1) "stays in the system" collapses three separate measurements into one phrase. The first is circulating persistence: how quickly an IGF-1 molecule is cleared from blood. The second is biomarker persistence: how long a measurable shift in serum IGF-1 concentration lasts after something changes the growth hormone (GH) axis. The third is biological persistence: how long the cellular consequences of IGF-1 signalling remain detectable in tissue after the hormone itself is gone. These three clocks run at very different speeds, and studies that measure one of them say nothing reliable about the other two.

A fourth complication is specific to IGF-1: it is endogenous. Unlike a synthetic research peptide that is either present or absent, IGF-1 is produced continuously, mainly in the liver under GH control, and circulates in every healthy person. There is no moment at which the body's IGF-1 concentration reaches zero, which is why questions framed as "how long until it is out" do not map cleanly onto the published measurements.

On half-life: what this evidence set does and does not contain

Transparency matters more than a tidy number. The verified papers summarised on this page do not include a human pharmacokinetic trial that measured and reported a plasma half-life for administered or endogenous IGF-1. Because no citation in this set supports such a figure, no half-life value in minutes or hours is stated here. Readers encountering confident single numbers elsewhere should check whether the source is a primary pharmacokinetic study in humans, a textbook generalisation, or an extrapolation from a different molecule entirely.

What the cited literature does support is the mechanism that governs IGF-1 residence time in blood. Circulating IGF-1 is almost entirely bound to IGF-binding proteins (IGFBPs) rather than free in plasma, and the binding state determines how much hormone is available to receptors. A 2024 study using antisense oligonucleotides to downregulate IGFBPs reported that reducing IGFBP expression enhanced IGF-1 signalling, which illustrates directly that binding-protein status — not the peptide's intrinsic chemistry alone — is a principal control point for how much IGF-1 is active and for how long. Researchers working on IGF-1 biology therefore treat "free", "bound" and "total" IGF-1 as distinct quantities with distinct kinetics.

How long a measured change in serum IGF-1 lasted

The most practically informative human data in this set concern the biomarker clock — how long serum IGF-1 remained altered after a drug acted on the GH axis. In a study of paltusotine, researchers reported that this novel oral once-daily nonpeptide somatostatin SST2 receptor agonist suppressed GH and IGF-1 in healthy volunteers. The relevant lesson for clearance questions is that a once-daily oral agent was sufficient to hold IGF-1 below baseline, meaning the serum IGF-1 signal responds to sustained upstream input rather than tracking a single short-lived pulse.

The mirror-image observation came from a study of somatrogon, a long-acting GH product given weekly. The study assessed IGF-1 during weekly somatrogon treatment in paediatric patients with GH deficiency, an investigation that exists precisely because IGF-1 concentrations are not flat across a weekly dosing interval — the timing of the blood draw relative to the last administration changes the number obtained. Researchers designing IGF-1 monitoring therefore treat sampling time as part of the measurement, not an afterthought.

Both observations point the same way: serum IGF-1 behaves as a slow, integrating biomarker of GH-axis activity over days, rather than as a fast on/off marker of a single exposure. That is the opposite of how short-acting synthetic peptides are usually described.

Route and formulation change residence at a site, not systemic half-life

A recurring theme in delivery research is that local formulation can extend how long a growth factor remains where it was placed, without necessarily changing what happens once the molecule reaches the bloodstream. A tissue-engineering study described sequential IGF-1 and BMP-6 releasing chitosan/alginate/PLGA hybrid scaffolds developed for periodontal regeneration, in which the release profile of IGF-1 was an engineered property of the carrier. Comparable work outside IGF-1 shows the same principle for peptides generally: a 2026 report described a self-assembling biomimetic peptide hydrogel that regulated tissue homeostasis to promote repair of persistent corneal epithelial defects, where the hydrogel itself provided sustained local presence. Those are formulation findings, not IGF-1 pharmacokinetic constants, and this page flags them as such.

Factors reported to change IGF-1 levels and clearance

Binding-protein status

Because IGFBPs sequester the hormone, anything altering IGFBP concentrations alters the free fraction. The antisense study cited above reported enhanced IGF-1 signalling after IGFBP downregulation, which is the clearest mechanistic illustration in this evidence set that the same total IGF-1 concentration can mean different biological exposure in different binding environments.

Nutrition and metabolic state

Metabolic status is a well-studied modifier of GH/IGF-axis hormones in animals. A study in ewes reported that glucogenic treatment created an altered metabolic milieu around the conception period, an example of nutrition-driven endocrine change measured in livestock rather than in humans. Findings of this type describe the direction in which metabolic inputs move endocrine measurements; they are not human pharmacokinetic data and are not presented as such.

Body size and species scaling

Pharmacokinetic parameters do not transfer between species without adjustment. A modelling paper presented an allometric pharmacokinetic/pharmacodynamic model for BI 893923, a novel IGF-1 receptor inhibitor. That compound is a small-molecule receptor inhibitor, not the IGF-1 peptide, so its parameters say nothing about IGF-1 itself — but the paper illustrates the standard practice of allometric scaling that underlies most cross-species clearance estimates, including the ones casually quoted for peptides.

Half-life engineering in related molecules

Medicinal chemistry routinely modifies molecules to extend duration. An early study described the discovery and biological characterisation of capromorelin analogues with extended half-lives. Capromorelin analogues are growth hormone secretagogues acting upstream of IGF-1, not IGF-1 analogues, so their half-lives are a property of that chemical series only. The general point the study reports is that half-life is a designable property of a molecule, which is why numbers from one GH-axis agent cannot be borrowed for another.

Detectability: what is and is not tested for

This is where plain language matters most. Routine workplace and clinical drug screens are configured to detect specific drug classes — typically substances of abuse such as amphetamines, cannabinoids, cocaine metabolites and opioids. They are immunoassays or chromatographic methods targeted at those analytes, and they do not look for peptide hormones or growth factors at all. Standard clinical chemistry panels measure a different set of analytes again, such as the liver enzyme alanine aminotransferase described in a 2024 reference summary of the ALT test; a test of that kind reports organ-function chemistry, not exogenous peptide exposure.

IGF-1 itself is measured in clinical practice, but as an endocrine biomarker rather than a drug screen. Assays quantify serum IGF-1 concentration and compare it with age- and sex-referenced ranges, which is how IGF-1 was used as the readout in the studies cited above on weekly somatrogon in paediatric GH deficiency. Because IGF-1 is endogenous, such an assay cannot distinguish "present" from "absent"; it can only report whether the concentration falls inside or outside a reference interval at the moment of sampling. Separately, as a regulatory fact, anti-doping authorities list IGF-1 and other growth factors among prohibited substances in sport, and anti-doping analysis uses dedicated methods that are unrelated to ordinary employment or clinical testing.

When effects outlast the molecule

The biological clock can run far longer than the circulating one. A 2025 study reported on targeting IGF-1-induced cellular senescence to rejuvenate hair follicle ageing, describing a cellular state induced by IGF-1 signalling rather than a transient hormone level. Cellular senescence itself is persistent and functionally consequential: separate work reported that senescent cells suppressed innate smooth muscle cell repair functions in atherosclerosis. Together these findings illustrate why "how long does it stay in the system" and "how long do its effects last" are not interchangeable questions in the published literature.

Safety observations in the cited studies: What Studies Report

The verified evidence set behind this page does not contain a human safety trial of administered IGF-1, and no adverse-event rates for exogenous IGF-1 are stated here for that reason. The human work cited involved agents acting on the GH axis rather than IGF-1 administration: researchers reported GH and IGF-1 suppression with once-daily oral paltusotine in healthy volunteers, and a separate study assessed IGF-1 during weekly somatrogon treatment in paediatric patients with GH deficiency. Beyond circulating levels, the hair-follicle study reported that IGF-1 signalling induced cellular senescence, a biological consequence rather than a clinical adverse event. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, laboratory result or medication.

Limits of this summary

• No human half-life value is given because no paper in the verified set reported one.
• Findings from scaffolds and hydrogels describe engineered local release, not systemic IGF-1 kinetics (scaffold study).
• Data from a small-molecule IGF-1 receptor inhibitor describe that compound only (allometric model).
• Animal endocrine findings, such as those in ewes, are species-specific (ewe study).

References

• Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 Signaling (Journal of Neuromuscular Diseases, 2024)
• Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers (Pituitary, 2022)
• IGF-1 Assessment During Weekly Somatrogon Treatment in Pediatric Patients With GH Deficiency (Journal of the Endocrine Society, 2025)
• Sequential IGF-1 and BMP-6 releasing chitosan/alginate/PLGA hybrid scaffolds for periodontal regeneration (International Journal of Biological Macromolecules, 2017)
• Self-assembling biomimetic peptide hydrogel regulates tissue homeostasis to promote repair of persistent corneal epithelial defects (Bioactive Materials, 2026)
• An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor (Cancer Chemotherapy and Pharmacology, 2017)
• Discovery and biological characterization of capromorelin analogues with extended half-lives (Bioorganic & Medicinal Chemistry Letters, 2002)
• Targeting IGF1-Induced Cellular Senescence to Rejuvenate Hair Follicle Aging (Aging Cell, 2025)
• Senescent cells suppress innate smooth muscle cell repair functions in atherosclerosis (Nature Aging, 2021)
• Alanine Aminotransferase (ALT) Test (StatPearls, 2024)
• Glucogenic treatment creates an optimal metabolic milieu for the conception period in ewes (Domestic Animal Endocrinology, 2017)